Cefbia S 250mg/125mg Injection
Marketer
Vybia Healthcare
Salt Composition
Ceftriaxone (250mg) + Sulbactam (125mg)
Overview Cefbia S 250mg/125mg Injection
Cefbia S 250mg/125mg Injection, a dual-action antibiotic, combats diverse bacterial infections by inhibiting microbial proliferation and halting infection progression. Administration must be strictly under a healthcare provider's guidance; consistent adherence to the prescribed schedule is crucial for optimal efficacy. Premature cessation can compromise treatment effectiveness, so complete the full course even with symptom improvement. Commonly reported side effects include nausea, vomiting, diarrhea, and dyspepsia. Severe or persistent side effects require immediate medical attention. Allergic reactions (rash, pruritus, edema, dyspnea) demand prompt emergency care. Inform your doctor about all current medications, including those for pre-existing conditions, before commencing treatment. Pregnant or lactating individuals should consult their physician. Alcohol consumption should be avoided due to potential increased drowsiness. While typically non-impairing, driving should be avoided if drowsiness or dizziness occur. Adequate rest, nutrition, and hydration promote faster recovery. Your doctor may order blood tests and imaging to monitor treatment response.
Uses of Cefbia S 250mg/125mg Injection
Infections caused by bacteria
Major Benefits of Cefbia S 250mg/125mg Injection:
This medication will be administered by your physician or their designated nurse. Self-medication is strongly discouraged.
Common Side effects of Cefbia S 250mg/125mg Injection:
- Increased white blood cell count (eosinophils)
- Decreased white blood cell count (lymphocytes)
- Low blood platelets
- Rash
- Diarrhea
- Increased liver enzymes
- Injection site reactions (pain, swelling, redness)
How to use Cefbia S 250mg/125mg Injection:
Administering this medication will be handled by your healthcare provider. Self-medication is strictly prohibited.
How Cefbia S 250mg/125mg Injection works:
Ceftriaxone and Sulbactam, combined as Cefbia S 250mg/125mg Injection, offer a dual-action approach to bacterial infections. The antibiotic Ceftriaxone disrupts bacterial cell wall synthesis, hindering their ability to reproduce. Sulbactam, a beta-lactamase inhibitor, complements this by overcoming bacterial resistance mechanisms, thereby maximizing Ceftriaxone's effectiveness.
SAFETY ADVICE
AlcoholSAFE
Cefbia S 250mg/125mg Injection use alongside alcohol consumption presents no known adverse reactions.
PregnancySAFE IF PRESCRIBED
The injection Cefbia S, containing 250mg/125mg, is typically deemed safe for use in pregnancy. Preclinical trials in animals revealed minimal or no negative consequences for fetal development; nevertheless, research involving pregnant humans is scarce.
Breast feedingCAUTION
The administration of Cefbia S 250mg/125mg Injection to breastfeeding mothers requires careful consideration. Lactation should be temporarily discontinued throughout the mother's course of treatment and until the medication is fully cleared from her system.
DrivingUNSAFE
The administration of Cefbia S 250mg/125mg Injection may induce drowsiness, blurred vision, or dizziness. Refrain from operating a vehicle if these effects manifest.
KidneyCONSULT YOUR DOCTOR
Data on Cefbia S 250mg/125mg Injection use in individuals with renal impairment is scarce. Physician consultation is advised.
LiverCAUTION
Exercise caution when administering Cefbia S 250mg/125mg Injection to individuals with severe hepatic impairment; dosage modification may be necessary. Consult a physician for guidance. Dosage alteration for Cefbia S 250mg/125mg Injection is unnecessary in patients exhibiting mild to moderate liver dysfunction.
What if you forget to take Cefbia S 250mg/125mg Injection :
Omitting a scheduled dose of Cefbia S 250mg/125mg Injection warrants immediate physician consultation.
Facts to Know About Cefbia S 250mg/125mg Injection
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Antimicrobials |
3,018 People bought this recently